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Infant colic is a common gastrointestinal disorder of newborns, mostly related to imbalances in the composition of gut microbiota
and particularly to the presence of gas-producing coliforms and to lower levels of Bifidobacteria and Lactobacilli. Probiotics
could help to contain this disturbance, with formulations consisting of Lactobacillus strains being the most utilized. In this work,
the probiotic strain Bifidobacterium breve B632 that was specifically selected for its ability to inhibit gas-producing coliforms,
was challenged against the Enterobacteriaceae within continuous cultures of microbiota from a 2-month-old colicky infant. As
confirmed by RAPD-PCR fingerprinting, B. breve B632 persisted in probiotic-supplemented microbiota cultures, accounting for
the 64% of Bifidobacteria at the steady state. The probiotic succeeded in inhibiting coliforms, since FISH and qPCR revealed that
the amount of Enterobacteriaceae after 18 h of cultivation was 0.42 and 0.44 magnitude orders lower (𝑃 < 0.05) in probiotic-
supplemented microbiota cultures than in the control ones. These results support the possibility to move to another level of study,
that is, the administration of B. breve B632 to a cohort of colicky newborns, in order to observe the behavior of this strain in vivo
and to validate its effect in colic treatment.
1. Introduction
In the first hours of life, the germ-free gastrointestinal tract of
newborns is colonized by microorganisms deriving from the
mother and from the environment, with the establishment
of a microbial community that will evolve into one of the
most complex microbial ecosystems [1]. The maintenance of
a correct balance of gut bacterial population is extremely
important since microbiota performs a variety of activities
and functions that deeply influence the health status of the
host, such as the metabolism of nondigestible compounds
with supply of short chain fatty acids, vitamin biosynthesis,
the regulation of immune system, and the prevention of
pathogen colonization [2, 3].
Despite the fact that increasing information about micro-
biota composition in adults is arising from metagenomics
and other culture-independent approaches, the dynamics of
initial colonization and evolution of the bacterial community
during the first days of life are poorly understood so far [4]. In
newborns, microbiota composition is variable and unstable,
and the establishment of the intestinal microbiota is highly
dependent on many factors, such as the mode of birth, breast
or formula feeding, and antibiotic intake [5–7]. Furthermore,
factors affecting the tropism and host-microbe interactions,
such as intestinal pH, body temperature, bile acids, peristalsis,
mucosal immune response receptors, and internal synergy,
exert a pivoting role in shaping the composition of bacte-
rial population [8, 9]. Initially, culturing studies indicated
that the pioneer bacteria colonizing the digestive tract of
newborns are Enterobacteriaceae and Gram-positive cocci
(e.g., Streptococcus, Staphylococcus), which lower the redox
potential and generate an anoxic environment, favorable
for the establishment of strictly anaerobic bacteria, such
as Bacteroidetes, Bifidobacterium, and Clostridiales [8, 10].
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Bifidobacteria are generally reported to prevail in the gut
microbiota of naturally delivered breast-fed infants after a few
days, at the expenses of Enterobacteriaceae and facultative
aerobes [11]. However, culture independent investigations
have provided evidence that infant colonizationmay bemuch
more complex, since it may be primed by anaerobes as well
(e.g. Clostridiales) and Bifidobacteria may not be among the
first colonizers or may remain a numerical minority [12].
Infant colic is a common functional gastrointestinal dis-
order of newborns, characterized by long bouts of crying and
hard-to-relieve behavior [13]. Crying peaks range between
6 and 12 weeks of age and cause considerable concern
and distress to parents. The pathogenesis of infant colic is
not well understood, and several underlying causes have
been suggested [13]. Among them, the relationship between
colonic microbiota and this disorder is emerging as a major
determinant. Culturing studies revealed higher counts of
Gram-negative bacteria and a less numerous population
of Lactobacilli and Bifidobacteria in the feces of colicky
infants compared with healthy infants [14]. Molecular global
investigation of the microbiota composition through phy-
logenetic microarray analysis demonstrated that gut micro-
biota differentiate much more slowly in colicky infants than
in healthy ones and that colic correlated positively with
the presence of specific genera of Gammaproteobacteria
(such as Escherichia, Klebsiella, Serratia, Vibrio, Yersinia,
and Pseudomonas) and negatively with bacteria belonging
to the Bacteroidetes and Firmicutes [15, 16]. Consistently, it
is known that Enterobacteriaceae, such as bacteria belong-
ing to Escherichia and Klebsiella, produce gas from mixed
acid fermentation and proinflammatory lipopolysaccharides,
both these mechanisms being proposed to favor colic
[17, 18].
The microbiota of colicky infants also presents lower
amounts of Bifidobacteria and Lactobacilli, which are known
to be anti-inflammatory and to exert various healthy prop-
erties [19–21]. The intake of probiotic Lactobacilli during
the first months of life can contribute to containing colic
[22, 23]. On the contrary, in vivo studies utilizing probiotic
Bifidobacteria for the treatment of colic are lacking.The strain
Bifidobacterium breve B632 possesses antimicrobial activity
against gas-producing coliforms isolated from the stools of
infants suffering from colic [24].
In order to obtain preliminary results that could support
an in vivo trial, the present study challenged B. breve B632
against the Enterobacteriaceae within cultures of microbiota
from a 2-month-old colicky infant. A continuous culture
fermentation simulating the gutmicrobiota of a colicky infant
was performed to examine the time-course of E. coli and
Enterobacteriaceae populations.
2. Methods
2.1. Chemicals and Bacterial Strain. All the chemicals were
supplied by Sigma (Stenheim, Germany), unless otherwise
stated. Bifidobacterium breve B632 was obtained from BUS-
CoB strain collection (Scardovi Collection of Bifidobacteria,
Dept. of Agro-Environmental Science and Technology, Uni-
versity of Bologna, Italy). The strain was accepted for deposit
by DSMZ for patent purposes and named B. breve DSMZ
24706. It was cultured anaerobically at 37∘C in Lactobacilli
MRS broth (BD Difco, Sparks, USA) containing 0.5 g/L L-
cysteine hydrochloride (hereinafter called MRS).
2.2. Cultures of Gut Microbiota. The cultures of gut micro-
biota were performed in a microbiota medium MM [25],
where the carbon source was substituted with 6.0 g/L of
a mixture of galactooligosaccharides (GOS, Domo Vivinal,
Needseweg, The Netherlands) and fructooligosaccharides
(FOS, Beneo-Orafti P95, Oreye, Belgium). The mixture was
composed of 90% GOS and 10% FOS (w/w), in agree-
ment with the composition of prebiotic infant formula [26].
Oligosaccharideswere filter-sterilized (0.22𝜇m)and added to
the medium after autoclaving.
Fresh feces from a breast-fed colicky infant, born by
natural delivery and not treated with antibiotics or probi-
otics, were utilized to prepare the inoculum for single-stage
continuous cultures. Inoculum preparation was performed







atmosphere. Feces were diluted to the ratio of 1 : 10 (w/v)
in MM, supplemented with 10% glycerol (v/v), and stored at
−80∘C until use.
In control microbiota cultures (MC), 5mL of fecal sus-
pension was thawed at 37∘C and utilized to inoculate bench-
top bioreactors (Sixfors V3.01, Infors, Bottmingen, Swiss)
containing 250mL of MM. Fresh MMwas fed at the dilution
rate of 0.042 h−1, corresponding to one turnover per day.
Themedium was flushed with CO
2
to maintain anaerobiosis.
The culture was kept in anaerobiosis at 37∘C, under gentle
agitation. Automatic titration with 4M NaOH maintained
pH at 6.5.
In probiotic-supplemented microbiota cultures (PMC),
fecal cultures were supplemented with 5.0 E + 7 cfu/mL of
B. breve B632. Concentrated stock cultures of B. breve B632
were supplementedwith glycerol (10%, v/v), enumerated onto
MRS-agar plates, and stored at −80∘C until an appropriate
volume was thawed and used for bioreactor inoculation.
Samples from MC and PMC were periodically collected
to analyze fermentation products, to examine the microbiota
composition, and to enumerate and isolate bifidobacteria.
2.3. Fluorescent In Situ Hybridization (FISH). FISH enumer-
ation of total bacteria, bifidobacteria, and Enterobacteriaceae
was based on the procedure of Harmsen et al. [27], with slight
modifications. Culture samples were diluted to the ratio of
1 : 4 with 40 g/L paraformaldehyde and incubated overnight
at 4∘C. Fixed cells were washed with PBS at pH 7.4 and then
dehydrated with PBS-ethanol 1 : 1 solution for 1 h at 4∘C. The
probes Eub 338, Bif 164, and Enterobact D, were used for total
bacteria, bifidobacteria, and Enterobacteriaceae, respectively
[28]. To perform hybridization, 10 𝜇L of cell suspension, 1 𝜇L
of the specific FITC-labeled probe, and 100 𝜇L of hybridiza-
tion buffer (20mM TRIS-HCl, 0.9M NaCl, and 0.1% SDS)
were mixed and incubated for 16 h at the temperature specific
for each probe [28].
A proper amount of the cell suspension was diluted in
4mL of washing buffer (20mM TRIS-HCl, 0.9M NaCl) and
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maintained at hybridization temperature for 10min before
being filtered onto 0.2𝜇m polycarbonate filters (Millipore,
Ettenleur, The Netherlands). Filters were mounted on micro-
scope slides with Vectashield (Vector Labs, Burlingame,
California). The slides were evaluated with a fluorescence
microscope (Eclipse 80i, Nikon Instruments) equipped with
mercury arc lamp, FITC specific filter, and digital camera.
Depending on the number of fluorescent cells, 30 to 100
microscopic fields were counted and averaged in each slide.
Each sample was enumerated in triplicate.
2.4. qPCR. Biomass samples from MC and PMC cultures
were collected by centrifugation, suspended in PBS (pH 7.8),
and extracted with QIAmp DNA Stool Mini Kit (Qiagen,
Hilden, Germany) to obtain bacterial gDNA. gDNA was
quantified with NanoPhotometer P-Class (Implen GmbH,
Munchen, Germany), diluted to 2.5 ng/𝜇L in TE buffer pH
8, and subjected to qPCR analysis with primers targeting
Enterobacteriaceae and Escherichia coli [29–31]. The set
of primers Eco-F (GTTAATACCTTTGCTCATTGA)/Eco-R
(ACCAGGGTATCAATCCTGTT) and Ent-F (ATGGCT-
GTCGTCAGCTCGT)/Ent-R (CCTACTTCTTTTGCAAC-
CCACTC) were used for Enterobacteriaceae and Escherichia
coli, respectively. The mixture contained 10 𝜇L of SsoFast
EvaGreen Supermix, 4 𝜇L of each 2𝜇M primer, and 2 𝜇L of
template. qPCR reaction was carried out with the CFX96
Real-Time System (Bio-Rad Laboratories, Redmond, WA,
USA), according to the following protocol: 98∘C for 2min;
45 cycles at 98∘C for 0.05min, 60∘C for 0.05min, and 95∘C
for 1min; 65∘C for 1min.
2.5. RAPD-PCR Tracing of Bifidobacterium breve B632. Fresh
culture samples were serially diluted in Wilkins-Chalgren
anaerobe broth (Oxoid) in the anaerobic cabinet and plated
on RB selective medium, in order to count and isolate
Bifidobacteria [32]. Genomic DNA was extracted from 200
colonies isolated from the PMC processes, using Instagene
matrix (Bio-Rad). RAPD-PCR was carried out in a 15 𝜇L
reaction mixture: 10X Dream Taq Buffer (including MgCl
2
2mM), 1.5 𝜇L; dNTPs mixture 0.10mM, 0,15 𝜇L; 2 𝜇M M13
primer (GAGGGTGGCGGTTCT), 3.75𝜇L; genomic DNA,
3 𝜇L; and PCR water 5.25 𝜇L. DNA amplification was per-
formed with the following protocol: 94∘C for 4min (1 cycle),
94∘C for 1min, 34∘C for 1min, 72∘C for 2min (45 cycles); 72∘C
for 7min (1 cycle). The PCR products were electrophoresed
in a 2% agarose gel (25 × 25 cm) for 4 h at a constant voltage
(160V) in TAE buffer (40mMTris-acetate, 1mM EDTA, and
pH 8.0). RAPD-PCR profiles were visualized under ultra-
violet light after staining with ethidium bromide, followed
by digital image capturing. The resulting fingerprints were
analyzed by the Gene Directory 2.0 (Syngene, UK) software
package. The similarity among digitalized profiles was calcu-
lated and a dendrogramwas derivedwith an unweighted pair-
group method using arithmetic means (UPGMA).
2.6. Analysis of Fermentation Products. The samples were
clarified through centrifugation (13,000×g, 5min, 4∘C) and
filtration (0.22𝜇mcellulose acetate filter) and stored at −20∘C
until analyzed. Fermentation products (formic, acetic, lactic,
propionic, butyric, and succinic acids and ethanol) were
analyzed using a HPLC device (Agilent technologies, Wald-
bronn, Germany) equipped with refractive index detector
and Aminex HPX-87 H ion exclusion column. Isocratic






2.7. Statistical Analysis. All values are means of four sepa-
rate experiments. Comparisons were carried out according
to Student’s 𝑡-test. Differences were considered statistically
significant for 𝑃 < 0.05.
3. Results
3.1. Evolution of Fecal Microbial Groups and Fermenta-
tion Products. Single-stage continuous fermentation of the
colonic microbiota from a colicky newborn was carried out
for 24 h to study whether the addition of B. breve B632
could affect the growth of Enterobacteriaceae. Bifidobacteria,
Enterobacteriaceae, and total bacteria were enumerated in
MC and in PMC, the latter supplemented with 5.0 E +
07 cfu/mL of B. breve B632 (Figures 1(a) and 1(b)). After 18 h
of cultivation, FISH bacterial counts became steady in both
MC and PMC cultures. Eubacteria increased up to 9.0–9.4 E+
09 cfu/mL, without statistically significant difference between
PMCandMC (𝑃 > 0.05). At all the time points, bifidobacteria
were more abundant in PMC than in MC (𝑃 < 0.05). Ente-
robacteriaceae were negatively affected by the presence of B.
breve B632 and were always less numerous in PMC than in
MC (𝑃 < 0.05).
The evolution of Enterobacteriaceae and E. coli was
determined also with q-PCR during the whole process.
Enterobacteriaceae were significantly lower in PMC than in
MC (𝑃 < 0.05), consistently with FISH results. On the other
hand, statistically significant difference was not observed
in the levels of E. coli (𝑃 > 0.05), with the exception of
18 h, when E. coli was less numerous in MC than in PMC
(Figure 2).
The presence of B. breve B632 in PMC cultures was
traced using RAPD-PCR fingerprinting at all the time points.
Colonies were isolated using the Bifidobacterium selective
medium RB and those positive to Bifidobacterium-specific
PCRwere subjected to RAPD-PCR analysis. At the beginning
of the fermentation, B. breve B632 represented the 85% of
bifidobacterial isolates in PMC, then decreased to 73% after
6 h, and stabilized at 64% at the steady state (𝑛 = 4, SD
< 34%). The relative amount of B. breve B632 tended to
decrease, albeit differences at the diverse time points were
not statistically significant. Considering that at the steady
state Bifidobacteria accounted for approximately 38% of
total eubacteria according to FISH enumeration, B. breve
B632 can be estimated as approximately the 24% of total
bacterial population in PMC. In these samples, 2 biotypes
of Bifidobacteria represented the autochthonous component.
The same two biotypes were identified also at the inoculum
in MC cultures, together with two other minor ones, none
of them exhibiting a RAPD-PCR profile similar to that of B.
breve B632.






































Figure 1: Time-course of total bacteria, bifidobacteria, and Enterobacteriaceae in cultures of infant gut microbiota. Eubacteria (),
Bifidobacterium (), and Enterobacteriaceae (◼) were quantified by FISH in control cultures (MC, (a)) and in cultures supplemented with B.
























Figure 2: Time-course of E. coli and Enterobacteriaceae in cultures
of infant gutmicrobiota.E. coli () andEnterobacteriaceae () were
quantified by qPCR in control cultures (MC, dashed line) and in
cultures supplementedwithB. breveB632 (PMC, solid line).Data are
means ± SD, 𝑛 = 4. Stars indicate statistically significant difference
between MC and PMC cultures (𝑃 < 0.05).
Formate, acetate, lactate, propionate, butyrate, and
ethanol originated by microbiota metabolism during the
processes (Figures 3(a) and 3(b)). Like the bacterial counts,
the concentrations of microbial products became stationary
after approximately 18 h. Ethanol, formate, lactate, and
acetate were the first to increase at the beginning of the
fermentation. Propionate, 2,3-butanediol, and butyrate
accumulated later, while lactate decreased as the steady state
was approached.
During the growth phase, the major differences between
MC and PMC processes were acetate and ethanol, accumu-
lating at different levels during the first hours of the process:
after 12 h, in MC and PMC, ethanol was 1.6 and 0.8 g/L,
while acetate 0.8 and 2.4 g/L, respectively. At the steady state
(18 h), MC had higher levels of butyrate and ethanol than
PMC, while acetate and lactate were higher in PMC (𝑃 <
0.05). The other metabolites exhibited similar steady-state
concentrations in PMC and MC processes (𝑃 > 0.05).
4. Discussion
Literature reports the use of Lactobacillus spp. strains to
alleviate the symptoms of infant colic [22, 23]. On the other
hand, no information is available on this specific use of
bifidobacteria, although in vitro results showed that strains of
Bifidobacterium can exert antimicrobial activity against gas
forming coliforms [24]. Among a panel of Bifidobacterium
strains that were selected as potential candidates for pro-
biotic use against colic in infants, B. breve B632 appeared
particularly promising because of its strong antimicrobial
activity against coliforms, coupled to the lack of transmis-
sible antibiotic resistance traits and cytotoxicity for the gut
epithelium. Moreover, the strain is capable of adhering to
gut epithelium cell lines and could stimulate gut health
by increasing metabolic activity and immune response of
epithelial cells [24].
In the present work, the antagonistic effect of B. breve
B632 against coliforms was challenged within gut microbiota
cultures of a colicky newborn, simulating in vivo conditions,
in order to propose its use as anticolic probiotic. B. breve
B632 survived well within the fecal culture, exhibiting a high
viability during the process. At all the time points, Enterobac-
teriaceae were significantly less numerous in presence of the
probiotic. These results indicate that B. breve B632 exerted

























Figure 3: Time-course of fermentation products in cultures of infant gut microbiota. Ethanol (), lactate (), acetate (△), formate (󳵳),
propionate (◻), 2,3-butanediol (◼), and butyrate (22C4) were determined in control cultures (MC, (a)) and in cultures supplemented with B.
breve B632 (PMC, (b)). Data are means, 𝑛 = 4, and SD always < 0.25 g/L.
antimicrobial activity against coliforms in fecal cultures as
well, consistently with previous observation with spot agar
tests and cocultures [24].
Unlike Enterobacteriaceae, E. coli counts were not
affected by the presence of the probiotic. This observation
can be ascribed to the different specificity of the primer
sets utilized in qPCR quantification, since the primers for
Enterobacteriaceae recognize a broader spectrum of species
than the ones for E. coli (Table 1).
Based on the list of species that align with qPCR primers
and FISH probes, it is likely that Gammaproteobacteria other
thanE. coli are involved in infant colic. For example, the qPCR
primers for Enterobacteriaceae should recognize Yersinia,
whereas the FISH probe for Enterobacteriaceae is expected
to miss it.
Fecal samples have amicrobial composition that does not
exactly correspond to that of the colonic content, wheremajor
microbial-host interactions occur, and richness and diversity
seem underrepresented [34]. However, systems as the one
herein described are currently the best tools to investigate the
external factors that could influence the intestinal microbial
composition such as antibiotics or to test novel potential
probiotics, before carrying out expensive in vivo trials. The
data herein presented indicate that the potential probiotic
strainB. breveB632was able to survive in a complexmicrobial
environment and restrained Enterobacteriaceae population.
5. Conclusions
The present study demonstrated the ability of a properly
selected probiotic Bifidobacterium strain B. breve B632 to
inhibit the growth of Enterobacteriaceae in an in vitromodel
system simulating the intestinal microbiota of a 2-month-old
colicky infant.These results support the possibility tomove to
another level of study, that is, the administration of B. breve
Table 1: Genera of human intestinal bacteria potentially recognized
by FISH probes and qPCR primers, according to SILVA.



























B632 to a cohort of colicky newborns, in order to observe the
behavior of this strain in vivo and to validate its effect in colic
treatment.
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